Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘mutatanome’

One of the pioneers and leading entrepreneurs in the development of personalised cancer vaccines is Professor Ugur Sahin.

In addition to being CEO of the privately-held biopharmaceutical company, BioNTech, he holds an academic appointment at the University of Mainz and is Managing Director of the translational research institute TRON.

This makes Mainz the perfect location for a cancer immunotherapy conference. It’s also where the Association for Cancer Immunotherapy (CIMT) is located. They were the local organisers of the 3rd annual CRI-CIMT-EATI-AACR cancer immunotherapy conference that we recently attended along with over 1400 people from around the world.

One of the underlying themes of the meeting and the posters was the development of personalised cancer vaccines, which is why we’re doing an extended mini-series based on interviews we did in Germany with leaders in the field.

Prof Sahin is a busy man, but we tracked him down in the poster hall. Here’s a brief excerpt from the impromptu interview he kindly gave to BSB.

Subscribers can log-in to read more of the latest thought leader interview or you can click to gain access to BSB Premium Content.

SITC 2015 National Harbor Gaylord MDNational Harbor, MD.  Today was a busy day with the ASH abstracts coming out this morning, and some ground-breaking data that demanded an immediate #ASH15 preview post.

At the same time we’re here at SITC, and keeping an eye on the AACR-NCI-EORTC Molecular Targets meeting – it’s like three buses come at once!

So what happened at SITC today? In this post we’ve put a quick summary of some of the presentations we heard on Day 2 that stood out.  Sometimes what’s most important is what people don’t say.

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

error: Content is protected !!